Transarterial chemoembolization with rivoceranib and camrelizumab for BCLC stage C hepatocellular carcinoma.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
rivoceranib-camrelizumab with TACE, and 84 received rivoceranib-camrelizumab alone
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Post-embolization symptoms occurred only in the TACE group but no grade 3-4 events were observed, and rates of systemic treatment-related adverse events were comparable between groups. [CONCLUSIONS] Adding TACE to rivoceranib-camrelizumab has the potential to improve tumor response and survival in BCLC stage C HCC without compromising safety.
[BACKGROUND] Transarterial chemoembolization (TACE) and systemic therapy are frequently applied for advanced hepatocellular carcinoma (HCC), but their combined therapeutic potential remains uncertain.
- p-value P = 0.006
APA
Zhu R, Zhang ZX, et al. (2025). Transarterial chemoembolization with rivoceranib and camrelizumab for BCLC stage C hepatocellular carcinoma.. Frontiers in oncology, 15, 1710686. https://doi.org/10.3389/fonc.2025.1710686
MLA
Zhu R, et al.. "Transarterial chemoembolization with rivoceranib and camrelizumab for BCLC stage C hepatocellular carcinoma.." Frontiers in oncology, vol. 15, 2025, pp. 1710686.
PMID
41450929
Abstract
[BACKGROUND] Transarterial chemoembolization (TACE) and systemic therapy are frequently applied for advanced hepatocellular carcinoma (HCC), but their combined therapeutic potential remains uncertain. Here, the clinical efficacy and safety of TACE together with rivoceranib plus camrelizumab in Barcelona Clinic Liver Cancer (BCLC) stage C HCC were investigated.
[METHODS] Between January 2021 and December 2024, 167 consecutive cases of BCLC stage C HCC were retrospectively analyzed. Eighty-three received rivoceranib-camrelizumab with TACE, and 84 received rivoceranib-camrelizumab alone. Comparisons of baseline characteristics, tumor response, long-term outcomes, and adverse events were conducted.
[RESULTS] Baseline variables were balanced between groups. Combination therapy achieved significantly higher partial (39.8% vs. 20.2%, P = 0.006) and objective response rates (50.6% vs. 29.7%, P = 0.006) than systemic therapy alone. Median progression-free survival (PFS: 11.0 vs. 9.0 months, P = 0.008) and overall survival (OS: 19.0 vs. 15.0 months, P = 0.001) were both longer in the combination group. Cox regression identified combined treatment as an independent predictor of extended PFS and OS. Post-embolization symptoms occurred only in the TACE group but no grade 3-4 events were observed, and rates of systemic treatment-related adverse events were comparable between groups.
[CONCLUSIONS] Adding TACE to rivoceranib-camrelizumab has the potential to improve tumor response and survival in BCLC stage C HCC without compromising safety.
[METHODS] Between January 2021 and December 2024, 167 consecutive cases of BCLC stage C HCC were retrospectively analyzed. Eighty-three received rivoceranib-camrelizumab with TACE, and 84 received rivoceranib-camrelizumab alone. Comparisons of baseline characteristics, tumor response, long-term outcomes, and adverse events were conducted.
[RESULTS] Baseline variables were balanced between groups. Combination therapy achieved significantly higher partial (39.8% vs. 20.2%, P = 0.006) and objective response rates (50.6% vs. 29.7%, P = 0.006) than systemic therapy alone. Median progression-free survival (PFS: 11.0 vs. 9.0 months, P = 0.008) and overall survival (OS: 19.0 vs. 15.0 months, P = 0.001) were both longer in the combination group. Cox regression identified combined treatment as an independent predictor of extended PFS and OS. Post-embolization symptoms occurred only in the TACE group but no grade 3-4 events were observed, and rates of systemic treatment-related adverse events were comparable between groups.
[CONCLUSIONS] Adding TACE to rivoceranib-camrelizumab has the potential to improve tumor response and survival in BCLC stage C HCC without compromising safety.
같은 제1저자의 인용 많은 논문 (5)
- Mechanistic Research on the Crosstalk Between Macrophage Polarization and Energy Metabolic Reprogramming in Hepatocellular Carcinoma.
- Multi-Machine Learning Elucidates Clinical Potential of Epithelial-Mesenchymal Transition-Associated Long Non-Coding RNAs in Breast Cancer Progression.
- Pbx1 overexpression delays cochlear hair cells degeneration in an accelerated aging mouse model.
- Deciphering the Cellular and Metabolic Landscape of Lymph Node Metastasis in Breast Cancer Using Single-Cell and Spatial Multi-Omics.
- Hepatokines and polycystic ovary syndrome: investigating the connection between the hepato-ovarian axis and disorders in glycolipid metabolism in PCOS: a narrative review.